Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis
[Journal of Alzheimer’s Disease, 65(2) (2018), 489–517, DOI 10.3233/JAD-180219]
https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180219
Table 3 was accidentally printed twice, with the correct Table 2 (starting on page 502) missing from the published article. The correct Table 2 is printed below.
Table 2
Author (year) | Agea and gender, % female | Prevalence of dementia (study sample) | Prevalence of anticoagulant use (study sample) | Prevalence of anticoagulant use in persons with dementia | Prevalence of anticoagulant use in persons without dementia | Odds ratiob (95% CI) |
Community or General Practice | ||||||
Choudhry (2006)[60] | Warfarin users (n = 50551) with identifiable providers = 76.2 (6.5), 48.3% | 1738/116200 (2%) | 50551/116200 (44%) | 556/1738 (32%) | 49995/114462 (43.7%) | 0.61 (0.55–0.67) |
Warfarin non-users (n = 65649) with identifiable providers = 77.2 (7.1) | ||||||
49% female | ||||||
Lopponen (2006)[69] | CVD+dem: 84.4 (5.7) | 85/409 (21%) | Warfarin use onlyd | 5/20 (25%) | 19/44 (43.2%) | 0.44 (0.14–1.42) |
CVD+no dem: 79.8 (4.4) | 24/64 (38%) | |||||
66% female | ||||||
Ewen (2012)[54] | 70 (13.3) | 87/1141 (8%) | 764/1141 (67%) | 55/87 (63%) | 709/1054 (67.3%) | 0.84 (0.53–1.32) |
48% female | ||||||
Holt (2012)[62] | Median agec (at AF diagnosis): 73.0 (IQR = 64.0–81.0), median age (in 2010, of 69762 registered in 2010): 80.0 years (IQR = 71.0–87.0) | 374/34041 (1%) | 18042/34041 (53%) | 108/374 (29%) | 17934/33667 (53.2%) | 0.36 (0.28–0.45) |
47% female | ||||||
Scowcroft (2012)[24] | 60–69 = 17054 (21%) 70–79 = 30350 (37%) 80+ = 33977 (42%) | 53825/81381 (7%) | 37119/81381 (46%) | 1376/5382 (26%) | 35761/75999 (47.0%) | 0.39 (0.36–0.41) |
52% female | ||||||
Mohammed (2013)[19] | 75.6 (11.7), 44% female | 2255/50361 (4%) | 24064/50361 (48%) | 567/2255 (25%) | 23497/48106 (48.8%) | 0.35 (0.32–0.39) |
Dreischulte (2014)[61] | 75.5 (no SD) | 1034/21096 (5%) | 8852/20443 (43% - all current anticoagulation), | 144/1006 (14%) | 8717/19437 (44.8%) | 0.21 (0.17–0.25) |
45% female | 11959/20443 (59% - anticoagulant ever since diagnosis) | |||||
Total prevalence: community setting | – | Data combined: | Data combined: | Data combined: | Data combined: | 0.40 (0.31–0.52) |
59398/304629 (20%) | 142523/303631 (47%) | 2811/10862 (26%) | 136632/292769 (47%) | |||
Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | |||
15 (23) | 50 (10) | 31 (15) | 50 (8) | |||
Hospital | ||||||
Deplanque (2004)[65] | Median age: 78 (range 29–101) | 82/370 (22%) | 82/288 (29%) | 4/41 (10%) | 78/329 (24%) | 0.35 (0.12–1.01) |
58% female | ||||||
Deplanque (2006)[66] | <65:30 (9.4%) | 38/320 (12%) | 186/320 (58%) | 7/38 (18%) | 179/282 (64%) | 0.13 (0.06–0.31) |
65–74:85 (26.6%) | ||||||
≥75:205 (64.1%) | ||||||
57% female | ||||||
Hylek (2006)[55] | 80 (no SD) | 51/405 (13%) | 206/405 (51%) | 8/51 (16%) | 198/354 (56%) | 0.15 (0.07–0.32) |
58% female | ||||||
Lefebvre (2006)[68] | Median age: 78.5 years (range: 54–101), 59% female | 24/204 (12%) | 53/204 (26%) | 2/24 (8%) | 51/180 (28%) | 0.23 (0.05–1.01) |
Partington (2007)[59],e | OAC | 22/106 (21%) | 57/106 (29%) | 12/22 (55%) | 45/84 (54%) | 1.04 (0.41–2.67) |
77.7 (8.6), 47% female | ||||||
No OAC | ||||||
82.0 (9.2), 42% female | ||||||
Doucet (2008)[67] | 84.7 (7) | 57/209 (27%) | 102/209 (49%) | 23/57 (40%) | 79/152 (52%) | 0.63 (0.34–1.16) |
61% female | ||||||
De Breucker (2010)[64] | 84 (5), 72% female | 65/111 (59%) | 57/111 (51%) | 35/65 (54%) | 22/46 (48%) | 1.27 (0.60–2.71) |
Tanislav (2014)[70] | 77.61 (8.6) | 241/1828 (13%) | 827/1828 (45%) | 67/241 (28%) | 760/1587 (48%) | 0.42 (0.31–0.56) |
58% female | ||||||
Formiga (2016)[50] | 82.7 (6) | 249/1225 (20%) | 99/1225 (8%) | 30/249 (12%) | 69/976 (7%) | 1.80 (1.14–2.83) |
74% female | ||||||
McGrath (2016)[20] | 79 (9) | 195/1405 (14%) | 786/1405 (56%) | 67/195 (34%) | 719/1210 (59%) | 0.36 (0.26–0.49) |
54% female | ||||||
Shah (2016)[17] | Median age (IQR) | 589/5781 (10%) | 4235/5781 (73%) | 377/589 (64%) | 3858/5102 (76%) | 0.57 (0.48–0.69) |
No OAC = 82 (75–87), OAC = 79 (73–85) | ||||||
Females | ||||||
No OAC 54.9% | ||||||
OAC 53% | ||||||
Total prevalence: Hospital setting | – | Data combined: | Data combined: | Data combined: | Data combined: | 0.49 (0.33–0.73) |
1613/11964 (13%) | 6690/11882 (56%) | 632/1572 (40%) | 6058/10302 (59%) | |||
Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | |||
20 (14) | 45 (18) | 31 (20) | 47 (20) | |||
Long-Term Care | ||||||
Latif (2005)[51] | 84.6 (no SD) | 66/117 (56%) | 54/117 (46%) | 26/66 (39%) | 28/51 (55%) | 0.53 (0.25–1.12) |
71% female | ||||||
Reardon (2013)[57] | NNHS database –median age 85 years 70% female | 1457/5211 (28%) | 2176/5211 (42%) | 462/1457 (32%) | 1714/3754 (46%) | 0.55 (0.49–0.63) |
AnalytiCare database - median age 83 years 63% female | ||||||
Bahri (2015)[63] | 87.1 (5.3) | 777/1085 (72%) | 541/1085 (50%) | 357/777 (46%) | 541/1085 (50%) | 0.86 (0.71–1.03) |
73% female | ||||||
Total prevalence: Long-Term Care setting | – | Data combined: | Data combined: | Data combined: | Data combined: | 0.66 (0.45–0.95) |
2300/6413 (36%) | 2771/6413 (43%) | 845/2300 (37%) | 2283/4890 (47%) | |||
Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | |||
52 (22) | 46 (4) | 39 (7) | 50 (5) | |||
Total for all studies combined | – | Data combined: | Data combined: | Data combined: | Data combined: | 0.48 (0.40–0.58) |
63311/323006 (20%) | 151984/321926 (47%) | 4288/14734 (29%) | 144793/307961 (47%) | |||
Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | Mean (%) (Std Dev): | |||
23 (21) | 47 (14) | 32 (17) | 48 (15) |